Amylyx Pharmaceuticals, Inc. Liquidation Value
AMLX
Other
Cash & Equivalents
$226.65M
As of 2025-12-31
Current Price: N/A
Key Metrics
Cash Liquidation Value
Cash minus Total Obligations
Cash: $226.65M
Total Obligations: -$28.64M
$198.01M
Per share: $1.80
Period: 2025-12-31
Liquid Liquidation Value
Cash + AR minus Total Obligations
Cash: $226.65M
AR: $88,000
Total Obligations: -$28.64M
$198.09M
Per share: $1.80
Period: 2025-12-31
Operating Liquidation Value
Cash + AR + Inventory minus Total Obligations
Cash: $226.65M
AR: $88,000
Inventory: $0
Total Obligations: -$28.64M
$198.09M
Per share: $1.80
Period: 2025-12-31
Build your own liquidation scenario
Adjust asset discounts and liability assumptions to see how assumptions affect the numbers.
Liquidation Ladder
| Metric | Total | Per Share |
|---|---|---|
| Cash Liquidation Value | $198.01M | $1.80 |
| Liquid Liquidation Value | $198.09M | $1.80 |
| Operating Liquidation Value | $198.09M | $1.80 |
Key Components (as of 2025-12-31)
| Cash & Equivalents | $226.65M |
| Accounts Receivable | $88,000 |
| Inventory | N/A |
| Current Liabilities | $22.69M |
| Long-term Debt | N/A |
| Op. Lease Liability | $5.96M |
| Finance Lease | N/A |
| Shares Outstanding | 109.9M |
Explore all 160 XBRL tags and build your own scenario → Open Calculator
Historical
| Period | Cash | AR | Inventory | AP | Curr Liab | LT Debt | Op Lease | Fin Lease |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $226.65M | $88,000 | N/A | $3.52M | $22.69M | N/A | $5.96M | N/A |
| 2025-09-30 | $225.18M | $132,000 | N/A | $5.34M | $25.79M | N/A | $5.93M | N/A |
| 2025-06-30 | $58.09M | $103,000 | N/A | $3.29M | $21.42M | N/A | $5.96M | N/A |
| 2025-03-31 | $59.76M | $300,000 | N/A | $4.81M | $17.93M | N/A | $1.38M | N/A |
▼ Community Notes